Metastatic Breast Cancer Central

SAN ANTONIO — Patients with metastatic breast cancer who take part in a supervised, structured exercise program during palliative treatment may experience improved quality of life, according to study results.

The treatment landscape for metastatic breast cancer has evolved tremendously within the past 2 decades.

All women with breast cancer should undergo genetic testing for BRCA1 and BRCA2 mutations, according to study findings presented at San Antonio Breast Cancer Symposium.

Although an abundance of treatments exist for breast cancer, there are almost no options for screening patients for risk for recurrence or spread of early-stage breast cancer, representing a major unmet need in the field.

SAN ANTONIO — Women aged 50 years or older who de-escalated to less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes to women who received annual mammography.

The addition of tucatinib to ado-trastuzumab emtansine significantly improved PFS among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to study findings.

Black and Hispanic women with early stage breast cancer in certain subgroups had worse survival rates compared with women of other races and ethnicities, according to results of a cohort study published in JAMA Network Open.

Significant advancements have been made in the de novo metastatic breast cancer space, including novel agents targeting the HER2 protein and others that enhance anti-estrogen therapies.

Patients with metastatic breast cancer treated with alpelisib as standard care had elevated blood glucose levels compared with those who received the drug as part of a clinical trial, according to data published in Cancer.

Ethnic and racial disparities are a major challenge throughout the field of oncology, but especially when it comes to treating metastatic breast cancer.